- Home
- KPRX vs AMBO Comparison
KPRX vs AMBO Comparison
Compare KPRX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- AMBO
- Stock Information
- Founded
- KPRX 1998
- AMBO 2000
- Country
- KPRX United States
- AMBO United States
- Employees
- KPRX N/A
- AMBO N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AMBO Other Consumer Services
- Sector
- KPRX Health Care
- AMBO Real Estate
- Exchange
- KPRX Nasdaq
- AMBO Nasdaq
- Market Cap
- KPRX 8.3M
- AMBO 7.1M
- IPO Year
- KPRX N/A
- AMBO 2010
- Fundamental
- Price
- KPRX $3.18
- AMBO $2.56
- Analyst Decision
- KPRX Strong Buy
- AMBO
- Analyst Count
- KPRX 1
- AMBO 0
- Target Price
- KPRX $10.00
- AMBO N/A
- AVG Volume (30 Days)
- KPRX 10.5K
- AMBO 11.7K
- Earning Date
- KPRX 05-09-2025
- AMBO 12-30-2024
- Dividend Yield
- KPRX N/A
- AMBO N/A
- EPS Growth
- KPRX N/A
- AMBO N/A
- EPS
- KPRX 0.87
- AMBO 0.11
- Revenue
- KPRX $16,020,000.00
- AMBO $9,392,000.00
- Revenue This Year
- KPRX N/A
- AMBO N/A
- Revenue Next Year
- KPRX N/A
- AMBO N/A
- P/E Ratio
- KPRX $3.56
- AMBO $24.81
- Revenue Growth
- KPRX N/A
- AMBO 2.50
- 52 Week Low
- KPRX $2.51
- AMBO $1.00
- 52 Week High
- KPRX $5.76
- AMBO $5.55
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- AMBO 52.56
- Support Level
- KPRX $2.64
- AMBO $2.45
- Resistance Level
- KPRX $3.25
- AMBO $3.14
- Average True Range (ATR)
- KPRX 0.19
- AMBO 0.29
- MACD
- KPRX 0.06
- AMBO -0.01
- Stochastic Oscillator
- KPRX 74.32
- AMBO 42.47
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.